Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up – Should You Buy?

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) gapped up before the market opened on Wednesday . The stock had previously closed at $20.53, but opened at $22.26. Structure Therapeutics shares last traded at $22.29, with a volume of 147,225 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research report on Thursday, December 19th. Finally, William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Price Performance

The business has a fifty day moving average price of $25.72 and a 200 day moving average price of $32.74. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -29.84 and a beta of -2.35.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. As a group, sell-side analysts predict that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Structure Therapeutics in the 4th quarter valued at $3,091,000. GF Fund Management CO. LTD. acquired a new position in Structure Therapeutics in the fourth quarter worth about $34,000. Woodline Partners LP raised its position in Structure Therapeutics by 0.7% in the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company’s stock worth $9,055,000 after purchasing an additional 2,328 shares in the last quarter. Vestal Point Capital LP lifted its stake in Structure Therapeutics by 50.0% during the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock worth $46,782,000 after purchasing an additional 575,000 shares during the period. Finally, Twinbeech Capital LP boosted its holdings in Structure Therapeutics by 34.3% during the fourth quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock valued at $767,000 after purchasing an additional 7,220 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.